154 related articles for article (PubMed ID: 32504368)
1. Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
Rosenberger LH; Thomas SM; Nimbkar SN; Hieken TJ; Ludwig KK; Jacobs LK; Miller ME; Gallagher KK; Wong J; Neuman HB; Tseng J; Hassinger TE; Jakub JW
Ann Surg Oncol; 2020 Oct; 27(10):3633-3640. PubMed ID: 32504368
[TBL] [Abstract][Full Text] [Related]
2. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
5. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
6. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
7. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
8. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
11. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
12. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
13. Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
Eccles DM; Li N; Handwerker R; Maishman T; Copson ER; Durcan LT; Gerty SM; Jones L; Evans DG; Haywood L; Campbell I
Ann Oncol; 2016 Mar; 27(3):467-73. PubMed ID: 26681682
[TBL] [Abstract][Full Text] [Related]
14. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
15. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
Arcand SL; Maugard CM; Ghadirian P; Robidoux A; Perret C; Zhang P; Fafard E; Mes-Masson AM; Foulkes WD; Provencher D; Narod SA; Tonin PN
Breast Cancer Res Treat; 2008 Apr; 108(3):399-408. PubMed ID: 17541742
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
17. Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Melhem-Bertrandt A; Bojadzieva J; Ready KJ; Obeid E; Liu DD; Gutierrez-Barrera AM; Litton JK; Olopade OI; Hortobagyi GN; Strong LC; Arun BK
Cancer; 2012 Feb; 118(4):908-13. PubMed ID: 21761402
[TBL] [Abstract][Full Text] [Related]
18. A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.
Giacomazzi J; Koehler-Santos P; Palmero EI; Graudenz MS; Rivero LF; Lima E; Pütten AC; Hainaut P; Camey SA; Michelli RD; Neto CS; Fitarelli-Kiehl M; Geyer G; Meurer L; Geiger A; Azevedo MB; da Silva VD; Ashton-Prolla P
Virchows Arch; 2013 Jul; 463(1):17-22. PubMed ID: 23794094
[TBL] [Abstract][Full Text] [Related]
19. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
Mittal A; Deo SVS; Gogia A; Batra A; Kumar A; Bhoriwal S; Deb KS; Dhamija E; Thulkar S; Ramprasad VL; Olopade O; Pramanik R
Ann Surg Oncol; 2022 Feb; 29(2):1423-1432. PubMed ID: 34601666
[TBL] [Abstract][Full Text] [Related]
20. Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
Lertwilaiwittaya P; Roothumnong E; Nakthong P; Dungort P; Meesamarnpong C; Tansa-Nga W; Pongsuktavorn K; Wiboonthanasarn S; Tititumjariya W; Thongnoppakhun W; Chanprasert S; Limwongse C; Pithukpakorn M
Breast Cancer Res Treat; 2021 Jul; 188(1):237-248. PubMed ID: 33649982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]